The content on this site is intended for healthcare professionals only
At a press conference at ECC 2015, Dr Lambertini presents the results of a meta-analysis suggesting that young women undergoing chemotherapy for breast cancer that may be more likely to remain fertile if they receive temporary treatment with a hormone-releasing hormone agonist (LHRHa).
A total of 12 randomized trials were included in the meta-analysis, accounting for 1,231 women with breast cancer.
The use of a LHRHa was found to significantly reduce the risk of chemotherapy-induced premature ovarian failure and seemed to be associated with a higher pregnancy rate in young breast cancer patients.
Watch the video interview and read the news story for more.
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Psychological issues in familial cancer
Multiple myeloma In Rwanda: The need for further research
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
Genomic testing: Awareness and effective communication between healthcare professionals and patients
OncoAlert round up July 28th to August 3rd, 2023
Advancing breast cancer treatment in Uganda by improving molecular testing
Somatic mutation profile of breast cancer in Uganda
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
